Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00656734 | Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer. | PHASE1 | COMPLETED | 27 | — | — | Apr 1, 2008 | Jun 1, 2010 | May 14, 2013 | 7 | United States |
| Arm | Type | Description |
|---|---|---|
| MDX 1411 | EXPERIMENTAL | Dose Escalation Cohorts |
| Name | Type | Description |
|---|---|---|
| MDX 1411 | BIOLOGICAL | MDX-1411 (fully human monoclonal antibody) administered as an i.v. infusion for up to 5 doses per cycle, with a maximum of 17 cycles total |
Inclusion Criteria: * Histologically confirmed diagnosis of RCC with clear cell component * Measurable disease * Treated with up to 6 prior systemic therapies for advanced/recurrent disease or have become intolerant to a systemic therapy * Subjects with treated brain metastases must be without magn...